The Getein 1600 and the Automation of Urgent Care Diagnostics

Getein 1600 Immunofluorescence Quantitative Analyzer | Fully Automated POCT Analyzer for High-Throughput Clinical Diagnostics

For decades, the tension in hospital diagnostics has been between speed and volume. Central labs process hundreds of samples per hour, but turnaround times — transport, batching, centrifugation — can stretch past an hour. At the bedside, rapid tests deliver answers in minutes, but they are manual, labour-intensive, and cap out at low throughput. The Getein 1600 is a response to that gap.

Built by Nanjing-based Getein Biotech, the 1600 is a fully automated immunofluorescence analyzer that integrates sample pipetting, dilution, incubation, and reading into a single workflow. It runs up to 150 tests per hour from a 48-sample rack, with a detection cycle under 30 seconds per cartridge and results available in 3 to 15 minutes. That throughput — sustained, not burst — is the key spec. It allows a busy emergency room to run cardiac markers, D-dimer, or procalcitonin continuously, without queuing or batching.

The automation is not trivial. Random-access loading means a clinician can spike a STAT troponin into a running batch without pausing the workflow — a feature that separates serious POCT platforms from semi-automated alternatives. Sample volume is as low as 10 microlitres, and the system accepts whole blood, serum, plasma, and urine. The Android-based 10.1-inch interface and LIS/HIS integration reflect a user experience designed for nurses and rotating residents, not trained lab technicians.

The implications for a hospital floor are concrete. A single device can replace a row of single-test fluorescent readers and the technician time needed to run them. In high-volume settings — a Chinese county hospital processing 400 outpatients per morning, or a Thai provincial ICU — the 45-kilogram footprint and 600-millimetre width mean it fits into existing bench space without renovation.

What the Getein 1600 reveals about China’s diagnostic supply chain is equally practical. Getein is one of several domestic IVD firms — Wondfo, Hotgen, Improve Medical — that have scaled automated immunoassay production over the last decade, largely in response to domestic demand for decentralised testing. These systems are built for cost sensitivity: the hardware is the lock, the reagent cartridges are the key. Procurement decisions in China’s volume-based public tenders favour platforms with transparent consumable pricing and high uptime, not brand premium.

Internationally, the 1600 competes on a simple value proposition: automated POCT throughput equivalent to a small benchtop chemistry analyser, at a fraction of the instrument and reagent cost. For a procurement officer evaluating a ward-level diagnostic upgrade, the real question is not whether the device works — fluorescence immunoassay is a mature method — but whether the hospital’s test menu aligns with the cartridge catalogue and whether the service network can respond within 24 hours.

The Getein 1600 is unglamorous infrastructure. But infrastructure is what determines whether a cardiac patient spends 15 minutes or 45 minutes waiting for a result before a treatment decision is made.

Why it matters:
For hospital administrators and lab directors, the 1600 represents a shift from point-of-care as a manual add-on to point-of-care as an automated, walkaway workflow. Its ability to sustain 150 tests per hour with random access makes it a viable alternative to routing urgent samples to a central lab.

View Product →